8,971 Shares in Cencora, Inc. $COR Purchased by SteelPeak Wealth LLC

SteelPeak Wealth LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,971 shares of the company’s stock, valued at approximately $2,804,000.

A number of other institutional investors also recently made changes to their positions in COR. Vanguard Group Inc. boosted its holdings in shares of Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after acquiring an additional 1,125,661 shares in the last quarter. Geode Capital Management LLC lifted its position in Cencora by 6.3% in the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after purchasing an additional 284,229 shares during the period. Norges Bank bought a new position in Cencora during the 2nd quarter valued at $695,215,000. Viking Global Investors LP increased its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares during the period. Finally, Amundi raised its stake in shares of Cencora by 17.0% in the 2nd quarter. Amundi now owns 1,720,278 shares of the company’s stock worth $500,893,000 after buying an additional 249,742 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the transaction, the chief executive officer owned 68,059 shares in the company, valued at approximately $23,374,863.55. The trade was a 6.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 20,317 shares of company stock valued at $7,009,260 over the last quarter. Company insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on COR. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research note on Monday. Mizuho raised their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Barclays started coverage on shares of Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 target price on the stock. Evercore ISI set a $400.00 target price on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $373.25.

Cencora Price Performance

COR stock opened at $338.87 on Friday. Cencora, Inc. has a one year low of $225.75 and a one year high of $377.54. The firm has a 50-day moving average of $349.59 and a two-hundred day moving average of $316.54. The firm has a market capitalization of $65.74 billion, a PE ratio of 42.63, a P/E/G ratio of 1.61 and a beta of 0.66. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a $0.60 dividend. The ex-dividend date was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is currently 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.